November 02, 2025

Get In Touch

PM Modi To Virtually Interact With Doctors, Pharma Firms Over COVID Situation

New Delhi: Prime Minister Narendra Modi will interact with leading doctors from across the country at 4.30 pm and with top pharma companies at 6 pm on the prevailing COVID-19 situation on Monday via video conference, officials said.
Earlier in the day, Modi had chaired an important meeting on the situation at 11:30 am.
Also Read: Doctors Write to PM Modi to stop VIP Culture during Pandemic
The meetings come amid a massive surge in coronavirus cases across the country, with several chief ministers complaining of a shortage of essentials like oxygen supply and medicines like Remdesivir, and seeking the Centre's intervention.
Modi has been holding regular meetings to deal with the emerging pandemic situation.
India's total tally of COVID-19 cases crossed the 1.50-crore mark with a record single-day rise of 2,73,810, while the active cases surpassed the 19-lakh mark, according to the latest Union Health Ministry data.
Also Read: Oral Steroids do not Increase Risk of COVID 19 in Patients of chronic rhinosinusitis

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!